Non-Alcoholic Steatohepatitis Biomarkers Market was valued at USD 1.2 Billion in 2022 and is projected to reach USD 3.5 Billion by 2030, growing at a CAGR of 15.8% from 2024 to 2030.
During the period from 2018 to 2022, several key factors contributed to the expansion of the NASH biomarkers market. The increasing global incidence of obesity, diabetes, and other metabolic conditions, combined with the growing number of patients developing NASH, led to heightened demand for accurate and reliable biomarkers. Moreover, the market saw technological advancements, such as the development of non-invasive diagnostic tools and the refinement of existing biomarkers, improving the ability to detect NASH early and monitor disease progression. The advent of precision medicine also played a crucial role in this period, as it enabled the identification of personalized treatment options based on specific biomarker profiles.
In addition, regulatory agencies such as the U.S. FDA accelerated the approval process for biomarkers used in NASH diagnosis, providing further momentum to the market. The increasing interest in NASH biomarkers has also attracted significant investments from pharmaceutical companies and biotechnology firms, spurring the development of innovative diagnostic tools and therapeutics.
Looking ahead to the forecast period from 2023 to 2033, the demand for NASH biomarkers is expected to continue its upward trajectory, driven by ongoing research and increasing awareness about NASH's long-term health consequences. The global market will likely see greater adoption of advanced technologies such as artificial intelligence (AI) and machine learning, which will enhance the accuracy of biomarkers and improve diagnostic procedures. Additionally, as the number of NASH patients increases worldwide, the need for efficient and accessible biomarker-based solutions for early detection and personalized treatment plans will become even more critical.
Furthermore, the development of novel biomarkers that can predict the progression of NASH to more severe stages, such as cirrhosis and liver cancer, will be a key focus for researchers and pharmaceutical companies. The regulatory landscape is expected to evolve with more biomarkers gaining approval for clinical use, broadening the scope of NASH diagnostics. Market dynamics will also be influenced by the integration of NASH biomarkers with other metabolic disease biomarkers, allowing for a more comprehensive understanding of the disease and its interplay with other conditions.
Get an In-Depth Research Analysis of the Global Non-Alcoholic Steatohepatitis Biomarkers Market Size And Forecast [2025-2032]
The Non-Alcoholic Steatohepatitis (NASH) biomarkers market has been witnessing significant growth from 2018 to 2022, as advances in medical research and increased awareness of the disease have driven demand for diagnostic and therapeutic biomarkers. NASH, a liver disease related to fatty liver, has emerged as a global health concern due to its rising prevalence. The biomarkers associated with NASH are critical for identifying patients at risk, assessing disease progression, and evaluating the efficacy of treatments. Market growth was fueled by the demand for diagnostic tests and therapies that could detect NASH in its early stages and monitor its progression effectively.
Genfit
Prometheus Laboratories
Siemens Medical Solutions USA
BioPredictive
Quest Diagnostics
AstraZeneca Plc.
Laboratory Corporation of America Holdings
Pfizer
Bristol-Myers Squibb Company
NGM Biopharmaceuticals
Gilead Sciences
Perspectum Diagnostics
One Way Liver SL
Enterome SA
Echosens SA
Cisbio Bioassays SAS
Celerion Inc.
Xeptagen SpA
Boehringer Ingelheim
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Non-Alcoholic Steatohepatitis Biomarkers Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Non-Alcoholic Steatohepatitis Biomarkers Market
Hospital
Pharmaceutical Company
Others
Based on Types the Market is categorized into Below types that held the largest Non-Alcoholic Steatohepatitis Biomarkers market share In 2023.
Hepatic Fibrosis Biomarkers
Serum Biomarkers
Oxidative Stress Biomarkers
Apoptosis Biomarkers
Others
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Non-Alcoholic Steatohepatitis Biomarkers Market Research Analysis
1. Introduction of the Global Non-Alcoholic Steatohepatitis Biomarkers Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Non-Alcoholic Steatohepatitis Biomarkers Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Non-Alcoholic Steatohepatitis Biomarkers Market, By Type
6. Global Non-Alcoholic Steatohepatitis Biomarkers Market, By Application
7. Global Non-Alcoholic Steatohepatitis Biomarkers Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/